Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Abdominal Neoplasm

Tundra lists 6 Abdominal Neoplasm clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT06212570

KeyScope Study in Uganda

KeyScope and KeyLoop (collectively called KeySuite) are laparoscopic prototypes that the investigators have designed for the resources, needs and challenges of low- and middle- income countries (LMICs). KeyScope is a laparoscope that plugs into a laptop computer to display images during surgery. It links to a telementoring application so that experienced surgeons can mentor surgeons in capacity-building partnerships. KeyLoop is a laparoscopic retractor that lifts the abdominal wall during surgery, obviating the need for a constant power supply and medical-grade carbon dioxide. The investigators will perform a clinical First-in-Human study at the Uganda Cancer Institute. Ugandan surgeons will use the KeySuite devices to perform biopsies of intra-abdominal tumors.

Gender: All

Updated: 2025-12-26

Abdominal Neoplasm
RECRUITING

NCT07113808

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China

The goal of this clinical trial is to evaluate the application of intravenous contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses. The main questions it aims to answer are: * Is intravenous contrast-enhanced ultrasound helpful for the diagnosis of intra-abdominal diseases in children? * What medical problems do participants have when participating in intravenous contrast-enhanced ultrasound examination? * How can ultrasound doctors conduct intravenous contrast-enhanced ultrasound examinations in a standardized manner? Researchers will performing intravenous contrast-enhanced ultrasound examinations on participants and collecting research subjects to establish a multicenter clinical data database. Participants will: * Perform abdominal ultrasound examination to assess the condition. * At least conduct one intravenous contrast-enhanced ultrasound examination. Based on the result of the contrast examination, decide whether to conduct another examination. * Keep a diary of their symptoms and therapeutic process in 30 days.

Gender: All

Ages: 29 Days - 18 Years

Updated: 2025-12-08

1 state

Abdominal Neoplasm
Abdominal Injury
Ascites
ACTIVE NOT RECRUITING

NCT05617755

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2025-07-30

7 states

Carcinoma, Ovarian Epithelial
Ovarian Neoplasms
Fallopian Tube Neoplasms
+6
RECRUITING

NCT05592626

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-09

20 states

Advanced Solid Tumors
Genital Neoplasm, Female
Urogenital Neoplasms
+9
RECRUITING

NCT06614179

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

Abdominal noncontrast scan and contrast-enhanced CT were used to establish a screening and diagnostic model for abdominal tumors

Gender: All

Ages: 18 Years - 75 Years

Updated: 2024-09-26

1 state

Abdominal Neoplasm
NOT YET RECRUITING

NCT06276738

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Evaluate LINFU® in patients who exhibit signs or symptoms (i.e. jaundice, abdominal pain, weight loss, nausea and vomiting etc.) suggestive of pancreatic cancer (PDAC) or have evidence of imaging studies suggestive of PDAC.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2024-05-14

Pancreatic Cancer
Jaundice
Abdominal Neoplasm